600089:SSETBEA Co., Ltd. Class A Analysis
Data as of 2026-06-14 - not real-time
CN¥23.03
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
TBEA is trading at CNY 23.03, comfortably below its 20‑day (CNY 25.43) and 50‑day (CNY 26.52) simple moving averages, indicating short‑term weakness, while the 200‑day SMA (CNY 23.69) sits just above the current price, suggesting a neutral longer‑term trend. The RSI of 31 points to oversold conditions and the MACD remains bearish (line below signal, negative histogram), which together hint at a possible near‑term bounce toward the support level around CNY 22.27. On the valuation side, the stock’s trailing PE of 19.2 is well under the industry average of 30.6, but the discounted cash‑flow fair value of CNY 15.96 is far below the market price, flagging a potential overvaluation from a cash‑flow perspective. Financially, the company carries a high debt load (total debt CNY 56.5 bn, debt‑to‑equity ≈ 54%) and negative free cash flow (‑CNY 21.3 bn), yet it maintains a modest dividend yield of 1.09% with a low payout ratio (~20%), supporting short‑term dividend sustainability.
Volatility is elevated at 40% over the past 30 days, but beta is only 0.58, implying limited market‑wide risk. Liquidity is strong, evidenced by rising volume and average daily volumes exceeding 130 million shares. The industrials sector presents moderate cyclical risk, while regulatory and geographic exposures are medium to high given China’s policy environment and the company’s domestic concentration. Overall, the mix of technical oversold signals, modest valuation relative to peers, and considerable balance‑sheet strain leads to a cautious stance across horizons.
Volatility is elevated at 40% over the past 30 days, but beta is only 0.58, implying limited market‑wide risk. Liquidity is strong, evidenced by rising volume and average daily volumes exceeding 130 million shares. The industrials sector presents moderate cyclical risk, while regulatory and geographic exposures are medium to high given China’s policy environment and the company’s domestic concentration. Overall, the mix of technical oversold signals, modest valuation relative to peers, and considerable balance‑sheet strain leads to a cautious stance across horizons.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Oversold RSI near 30
- Support level at CNY 22.27
- Increasing volume indicating buying interest
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Price below 20‑day and 50‑day SMAs
- Bearish MACD trend
- High debt and negative free cash flow
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- DCF fair value well under market price
- Modest dividend yield with low payout ratio
- Exposure to China’s regulatory and policy environment
Key Metrics & Analysis
Financial Health
Revenue Growth6.80%
Profit Margin6.24%
P/E Ratio19.2
ROE6.58%
ROA2.04%
Debt/Equity53.87
P/B Ratio1.6
Op. Cash FlowCN¥8.8B
Free Cash FlowCN¥-21321840640
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI31.3
SupportCN¥22.27
ResistanceCN¥27.37
MA 20CN¥25.43
MA 50CN¥26.52
MA 200CN¥23.69
MACDBearish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair ValueCN¥15.96
GradeFair
TypeBlend
Dividend Yield1.09%
Risk Assessment
Beta0.58
Volatility40.71%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.